Who
Muneer A. Satter
Director
Company insider
Files Form 4 as: Director and 10% owner, Annexon; Director and Officer and 10% owner, Rein Therapeutics; Director and 10% owner, Whitehawk Therapeutics; Director and 10% owner, Immunic; Director, Akebia Therapeutics; 10% owner, Eledon Pharmaceuticals; 10% owner, HeartWare International.
In numbers
- Trades disclosed
- 144
- Buys
- 85
- Sells
- 3
- Bought
- $126.4M
- Sold
- $4.1M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 14 Apr 2008
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $3.3M613,497 at $5.41 | filing |
| 28 May 2026filed 29 May 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $3.3M613,497 at $5.41 | filing |
| 21 Nov 2025filed 21 Nov 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $1.8M422,613 at $4.28 | filing |
| 20 Nov 2025filed 21 Nov 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $1.8M400,000 at $4.48 | filing |
| 19 Nov 2025filed 19 Nov 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $2.0M500,000 at $3.94 | filing |
| 18 Nov 2025filed 19 Nov 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $1.6M500,000 at $3.18 | filing |
| 17 Nov 2025filed 19 Nov 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $1.5M500,000 at $2.99 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 26 Dec 2023filed 28 Dec 2023 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $1.0M350,000 at $2.88 | filing |
| 8 Jun 2023filed 12 Jun 2023 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 10 Feb 2023filed 14 Feb 2023 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $18.0M2,647,058 at $6.80 | filing |
| 7 Jul 2022filed 11 Jul 2022 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code P | $80K613,497 at $0.13 | filing |
| 7 Jul 2022filed 11 Jul 2022 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $9.4M2,453,988 at $3.84 | filing |
| 9 Jun 2022filed 13 Jun 2022 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 2 Jun 2021filed 4 Jun 2021 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jan 2021filed 8 Jan 2021 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $9.9M9,000,000 at $1.10 | filing |
| 28 Jul 2020filed 28 Jul 2020 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,095,238 | filing |
News
No headline names them, or the companies they trade most, lately.